AN IMMUNOLOGICAL STUDY OF THE A SUBSTANCE OR ACETYL POLYSACCHARIDE OF PNEUMOCOCCUS TYPE I.

J Exp Med

Department of Bacteriology and Immunology, The Harvard Medical School, Boston.

Published: July 1934

1. The A carbohydrate isolated from Type I pneumococcus by Pappenheimer and Enders, on the basis of elementary analysis, the presence of the acetyl group and its immunological properties, appears to be identical with the acetyl polysaccharide described by Avery and Goebel. 2. The A carbohydrate possesses a greater anti-opsonic action than either the deacetylated substance obtained by boiling in alkali or the soluble specific substance of Type I pneumococcus prepared according to the procedure of Heidelberger, Goebel and Avery. The opsonic titre of normal human serum is practically eliminated upon the addition of the A carbohydrate-an effect not observed with equivalent amounts of either the deacetylated material or the specific soluble substance. In immune serum, the A carbohydrate brings about a quantitatively greater reduction in opsonic activity than its derivatives, but it has not been possible to demonstrate complete inhibition of phagocytic action by the method of absorption of antibody. 3. In a system of normal human serum and leucocytes capable of destroying Type I pneumococcus, the bactericidal effect maybe entirely removed upon the addition of the A carbohydrate. It proved impossible to inactivate the bactericidal action with the deacetylated substance in equivalent proportions. In this system, the A carbohydrate was about 64 times more effective as an antibactericidal agent than the deacetylated compound. Essentially similar results were obtained in a study of the antibactericidal properties of the A carbohydrate and the deacetylated derivative in the presence of anti-Type I pneumococcus rabbit serum added to a mixture of exudative leucocytes and the defibrinated blood of the rabbit. 4. The mouse-protective titre of anti-Type I pneumococcus rabbit serum is lowered to a greater degree after absorption with the A carbohydrate than it is by similar treatment with the deacetylated compound. Absorption with the A carbohydrate does not, however, completely remove the protective antibody. 5. As Avery and Goebel have shown in the case of the acetyl polysaccharide, so the A carbohydrate, when administered in very small quantities, protects mice against an otherwise fatal dose of Type I pneumococcus. Active immunity in mice has been obtained with as little as 0.00005 mg. of the A carbohydrate administered in a single dose. Doses larger than 0.005 mg. confer no protection on these animals. Deacetylization of the A carbohydrate after boiling in N/10 sodium hydroxide destroys its protective capacity while similar treatment in N/50 alkali does not completely remove its immunizing property. Active immunity may arise within 3 days following a single injection of the A substance. It appears to be at its height from 6 to 25 days thereafter, and is retrogressive by the 49th day following vaccination. Injection of the A carbohydrate into immunized mice immediately before infection deletes the state of resistance. 6. The immunity actively induced as a result of injection of the A carbohydrate may be passively transferred to normal mice with the serum of vaccinated animals. 7. Since the evidence obtained in the course of this study indicates that the A carbohydrate of Type I pneumococcus and the acetyl polysaccharide of Avery and Goebel represent the same chemical substance, it is suggested that the designation "A carbohydrate" or "A substance" be relinquished in favor of the more exactly descriptive term "acetyl polysaccharide."

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2132394PMC
http://dx.doi.org/10.1084/jem.60.2.127DOI Listing

Publication Analysis

Top Keywords

type pneumococcus
20
acetyl polysaccharide
16
carbohydrate
14
avery goebel
12
pneumococcus
8
action deacetylated
8
deacetylated substance
8
normal human
8
human serum
8
deacetylated compound
8

Similar Publications

Modeling and simulation of distribution and drug resistance of major pathogens in patients with respiratory system infections.

BMC Infect Dis

January 2025

Department of Respiratory Medicine, Anting Hospital of Jiading District, 1060 Hejing Road, Anting Town, Jiading District, Shanghai, 201805, China.

Background: Respiratory tract infections (RTIs) are one of the leading causes of morbidity and mortality worldwide. The increase in antimicrobial resistance in respiratory pathogens poses a major challenge to the effective management of these infections.

Objective: To investigate the distribution of major pathogens of RTIs and their antimicrobial resistance patterns in a tertiary care hospital and to develop a mathematical model to explore the relationship between pathogen distribution and antimicrobial resistance.

View Article and Find Full Text PDF

Exposure to influenza A virus (IAV), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) is well-known to increase the risk of pneumonia in humans. Type I interferon (IFN-I) is a hallmark response to acute viral infections, and alveolar macrophages (AMs) constitute the first line of airway defense against opportunistic bacteria. Our study reveals that virus-induced IFN-I receptor (IFNAR1) signaling directly impairs AM-dependent antibacterial protection.

View Article and Find Full Text PDF

Unlabelled: During infection, bacterial pathogens rely on secreted virulence factors to manipulate the host cell. However, in gram-positive bacteria, the molecular mechanisms underlying the folding and activity of these virulence factors after membrane translocation are not clear. Here, we solved the protein structures of two secreted parvulin and two secreted cyclophilin-like peptidyl-prolyl isomerase (PPIase) ATP-independent chaperones found in gram-positive streptococcal species.

View Article and Find Full Text PDF

Introduction: Pneumococcal diseases (PD) caused by include invasive PD (IPD) and non-bacteremia pneumococcal pneumonia (NBPP). Current French vaccination guidelines FOCUS on patients with underlying medical conditions (UMC) who are at a higher risk of PD. This study describes the healthcare resource utilization (HCRU) and economic burden of inpatient PD in French adults, to inform vaccination guidelines, especially among vulnerable subpopulations at increased risk of PD.

View Article and Find Full Text PDF

Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally.

Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!